Research programme: disease-associated protein targets - CAT/Xerion

Drug Profile

Research programme: disease-associated protein targets - CAT/Xerion

Alternative Names: Disease-associated protein targets research programme – CAT/Xerion

Latest Information Update: 08 May 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cambridge Antibody Technology; Xerion Pharmaceuticals
  • Developer Xerion Pharmaceuticals
  • Class Antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 22 Jun 2006 No development reported - Preclinical for Undefined in Germany (unspecified route)
  • 22 Jun 2006 Cambridge Antibody Technology has been acquired by AstraZeneca
  • 23 Sep 2003 Preclinical trials in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top